Solid Biosciences director awarded 77,500 options

Solid Biosciences Inc. director Georgia Keresty received a new stock option grant.

Rhea-AI Filing Summary

Solid Biosciences Inc. director Georgia Keresty received a new stock option grant. On June 10, 2026, she was awarded options for 77,500 shares of common stock at an exercise price of $6.61 per share. These options vest in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, and will also fully vest upon specified change in control events. Following this grant, her reported derivative holdings from this award total 77,500 options, expiring on June 10, 2036.

Insider Trade Summary

Grant/Award: 77,500 shares

Grant/Award 1 txn

Insider Keresty Georgia

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	77,500	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 77,500 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Key Figures

Option grant size: 77,500 shares Exercise price: $6.61 per share Shares after transaction: 77,500 derivative shares +2 more

5 metrics

Option grant size 77,500 shares Director stock option grant on June 10, 2026

Exercise price $6.61 per share Director stock option grant

Shares after transaction 77,500 derivative shares Total options held from this award after grant

Expiration date June 10, 2036 Option term end for director grant

Grant date June 10, 2026 Date director stock option was awarded

Key Terms

Director Stock Option (Right to Buy), grant/award acquisition, annual meeting of stockholders, change in control events

4 terms

Director Stock Option (Right to Buy) financial

"security_title: Director Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

annual meeting of stockholders financial

"immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date"

change in control events financial

"will vest automatically as to 100% of the unvested portion of such option upon specified change in control events"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did director Georgia Keresty receive in this Solid Biosciences (SLDB) Form 4?

Georgia Keresty received a stock option grant for 77,500 shares of Solid Biosciences common stock. The options have a $6.61 exercise price per share and represent a compensation-related award rather than an open-market stock purchase or sale.

When do Georgia Keresty’s new Solid Biosciences (SLDB) stock options vest?

The options vest in full on the earlier of one year after the June 10, 2026 grant date or immediately before Solid Biosciences’ next annual meeting. They can also fully vest if specified change in control events occur, accelerating vesting of any remaining unvested portion.

What is the exercise price and size of the Solid Biosciences (SLDB) option grant?

The grant covers 77,500 underlying shares of Solid Biosciences common stock with an exercise price of $6.61 per share. This price is what must be paid per share to exercise the option once it is vested and exercisable.

How long do Georgia Keresty’s Solid Biosciences (SLDB) options remain outstanding?

The options expire on June 10, 2036, giving a 10-year term from the June 10, 2026 grant date. If not exercised by that expiration date, any unexercised portion will lapse and no longer provide the right to buy shares.

How many Solid Biosciences (SLDB) derivative securities does Georgia Keresty hold after this grant?

After the reported transaction, Georgia Keresty holds 77,500 derivative securities from this option grant. This figure reflects the total shares underlying the newly awarded director stock option as reported in the Form 4 transaction details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keresty Georgia

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MASSACHUSETTS 02129

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$6.61	06/10/2026		A		77,500		(1)	06/10/2036	Common Stock	77,500	$0.00	77,500	D

Explanation of Responses:

1. This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

	/s/ by Kimberly Cornwell as attorney-in-fact for Georgia Keresty	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)